title: The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?
authors.affiliation: McMaster University, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada. searsm@mcmaster.ca
authors.forename: Malcolm R
authors.initials: MR
authors.lastname: Sears
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D011358:Product Surveillance, Postmarketing; D000068299:Salmeterol Xinafoate; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D004983:Ethanolamines; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate